“2025 is off to a strong start for Tenaya as we delivered positive data from our MyPEAK-1 clinical trial evaluating TN-201 for the potential treatment of MYBPC3-associated HCM, shared new findings from the RIDGE natural history study of adults with PKP2-associated ARVC, and extended our cash runway into the second half of 2026,” said Faraz Ali, Chief Executive Officer of Tenaya. “We are pleased to report that patient enrollment is on track for both the MyPEAK-1 study for TN-201 and the RIDGE-1 study for TN-401 as we drive both programs toward meaningful clinical readouts in the second half of this year. We have also taken important steps to focus our financial resources on clinical execution to help ensure we can take TN-201 and TN-401 through to important clinical milestones in 2026.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Promising Outlook for Tenaya Therapeutics: Buy Rating Justified by Innovative Gene Therapy Potential
- Tenaya announces interim data from ongoing RIDGE study
- Promising Outlook for Tenaya Therapeutics: Buy Rating Backed by Strategic Advantages and Market Opportunities
- Promising Phase 1b/2 Results for Tenaya’s TN-201 Support Buy Rating
- Buy Rating Affirmed for Tenaya Therapeutics Amid Promising TN-201 Data and Financial Stability
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue